NCT04394689View on ClinicalTrials.gov

Measles and Rubella Vaccine Microneedle Patch Phase 1-2 Age De-escalation Trial

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

281

Participants

Timeline

Start Date

May 19, 2021

Primary Completion Date

November 23, 2022

Study Completion Date

December 31, 2022

Conditions
MeaslesRubellaVaccinationHealthy
Interventions
BIOLOGICAL

Measles Rubella Vaccine (MRV-SC)

One dose as subcutaneous injection of a WHO prequalified MR vaccine

BIOLOGICAL

MRV-MNP

One standard dose of Measles and Rubella vaccine delivered intradermally as a dissolving microneedle patch

OTHER

PLA-MNP

One placebo dose of a dissolving microneedle patch

OTHER

PLA-SC

Placebo saline as subcutaneous injection

Trial Locations (1)

Unknown

Medical Research Center The Gambia at LSHTM, Fajara

Sponsors

Collaborators (1)

Medical Research Council
All Listed Sponsors
collaborator

Medical Research Council

OTHER_GOV

collaborator

Centers for Disease Control and Prevention

FED

lead

Micron Biomedical, Inc

INDUSTRY